You're listening to this week in cardiology from the heart.org on medscape.

You can now access the latest in medical news on your Amazon Alexa enabled device.

Join me, Perry Wilson, every weekday morning for Medscape Medical Minute,

where I highlight the top medical stories of the day.

To add Medscape Medical Minute to your flash briefing, search for Medscape Medical

Minute on Amazon and click enable. Or open the Amazon Alexa app, go to Skills, search for Medscape

Medical Minute and click enable. Then say,

Alexa, what's the news or Alexa, what's my flash briefing? I hope you'll join us.

Hi everyone, this is John Mandrola from the Heart.org Medscape Cardiology and this is this week in

Cardiology for February 7th, 2020.

This week, a New England Journal of Medicine Retraction, Taver, ICDs, Long QT Syndrome, and Screening.

First, I want to start with a correction.

In the last podcast, I mistakenly said the Improvit trial which was Simpestat and Azetamib when I meant

reduce it which is Icosopent Ethel. Sorry for that and thanks to the many listeners who noticed the error.

Let's start this week with the huge news of the high profile New England Journal of Medicine

retraction.

Like many stories on this podcast, I try to pick topics that have both specific and larger messages.

When a New England Journal of Medicine retracted a 2018 paper on ambulatory blood pressure measurements,

the news specifically affected how we think about blood pressure

and mortality, but more generally and more importantly, the retractions informs how we think about

the trustworthiness of traditional peer review.

Let's start with the concluding sentence from the editorial at that time the paper was published,

...